Get the Daily Brief
Latest Biotech News
Danaher Posts Revenue Growth Despite China Headwinds
Danaher’s Q2 revenue rose nearly 4% year-over-year to $5.94 billion, beating estimates driven by robust bioprocessing sales. Despite ongoing headwinds from China’s volume-based procurement and...
New Insights into Brain Aging Acceleration During COVID-19 Pandemic
A study analyzing brain scans from nearly 1,000 individuals revealed accelerated brain aging in healthy people during the COVID-19 pandemic, regardless of infection status. The effect was most...
Advances in Molecular Diagnostic Automation from Genetic Signatures Partnership
Australian molecular diagnostics firm Genetic Signatures formed a partnership with Tecan and Repado to integrate infectious disease testing with automated liquid handling and regulatory compliant...
Sanofi Expands Respiratory Vaccine Pipeline With $1.15B Vicebio Buyout
Sanofi has agreed to acquire UK-based biotech Vicebio in a deal totaling up to $1.6 billion, including $1.15 billion upfront. Vicebio’s lead asset, VXB-241, a bivalent vaccine targeting...
Sarepta Therapeutics Faces Regulatory and Safety Challenges Over Duchenne Gene Therapy
Sarepta Therapeutics has temporarily halted shipments of its Duchenne muscular dystrophy gene therapy, Elevidys, following safety concerns that include three patient deaths tied to acute liver...
FDA Rejects Replimune’s Oncolytic Virus Therapy for Advanced Melanoma
The FDA issued a complete response letter rejecting Replimune’s application for RP1, an oncolytic virus therapy designed to treat advanced melanoma. The agency cited inadequacies in trial design,...
AstraZeneca Commits $50B to U.S. Manufacturing and R&D Expansion
AstraZeneca announced a $50 billion investment plan to enhance its manufacturing and research operations in the United States through 2030. The expansion includes building the company’s...
Early Clinical Progress in Extracellular Vesicle-Based Drug Delivery in Asia-Pacific
Asia-Pacific startups like Shiftbio are leveraging extracellular vesicle (EV) technology for next-generation drug delivery systems. Shiftbio’s AI-powered nanoparticle design and manufacturing...
Alzheimer’s Disease Research Identifies Potential Combination Therapy Using Repurposed Cancer Drugs
Researchers at UCSF and Gladstone Institutes have identified a combination of FDA-approved anticancer drugs, letrozole and irinotecan, that reversed Alzheimer’s-related brain degeneration and...
New Prime Editing Approach Corrects Genetic Mutations in Rare Childhood Brain Disorder
A collaborative team led by the Broad Institute successfully employed prime editing to correct five distinct mutations responsible for alternating hemiplegia of childhood (AHC) in mouse models....
Genetic Discoveries Shed Light on Human Brain Evolution and Function
Using the recently completed telomere-to-telomere human genome reference, researchers identified approximately 250 human-specific gene duplications expressed in the brain. By creating CRISPR...
New Study Reveals Fungus Enhances Bread Wheat Micronutrient Content
Researchers from the University of Adelaide demonstrated that inoculating bread wheat with the arbuscular mycorrhizal fungus Rhizophagus irregularis increases grain size and raises levels of...
Biogen Announces $2B Expansion of Manufacturing Capacity in North Carolina
Biogen plans to invest an additional $2 billion over the next three years to expand operations at its Research Triangle Park campuses in North Carolina. The expansion will enhance multiple...
Sarepta Duchenne Gene Therapy Shipment Paused amid Safety Concerns
Sarepta Therapeutics has voluntarily paused shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following FDA requests amid safety concerns linked to acute liver failure and...
Sanofi Buys Vicebio for $1.15 Billion to Expand Respiratory Vaccine Portfolio
Sanofi has agreed to acquire UK-based respiratory vaccine specialist Vicebio for $1.15 billion upfront plus up to $450 million in development and regulatory milestones. The acquisition brings...
AstraZeneca Pledges $50 Billion U.S. Investment for Manufacturing and R&D
AstraZeneca unveiled plans to invest $50 billion in U.S. manufacturing and research operations through 2030, over a 14-fold increase from previous commitments. Key components include constructing...
FDA Leadership Change: George Tidmarsh Named CDER Director
FDA Commissioner Marty Makary named George Tidmarsh, an accomplished physician-scientist and biotech executive with oncology and pediatrics expertise, as the new director of the Center for Drug...
FDA Rejects Replimune’s Oncolytic Virus Therapy for Melanoma
The FDA issued a complete response letter rejecting Replimune's melanoma drug candidate RP1, an oncolytic virus therapy combined with nivolumab, citing inadequate and uncontrolled clinical trial...
Breakthrough: Prime Editing Corrects Mutations in Rare Neurological Disorder
Researchers from the Broad Institute and Jackson Laboratory demonstrated in a mouse model that prime editing can correct five genetic mutations causing alternating hemiplegia of childhood (AHC), a...
Novel Therapies and Clinical Advances in Immunotherapy and Neurology
Multiple studies highlight progress in immunotherapy and neurological diseases. Engineered IL-18 variants with improved pharmacological properties show promise for cancer treatments. Myogenic...